-
-
-
-
-
-
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX) following management changes
-
-
-
-
-
-
-
BioNTech SE (BNTX) Misses Q2 EPS by 19c; reaffirms guidance
-
-
-
-
-
-
-
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
-
-
-
-
-
-
-
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
-
-
-
-
-
-
-
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
-
-
-
-
-
-
-
BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discus
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mercury Systems, Onsemi, BioNTech, and BioVie and Encourages Investors to Contact the Firm
-
1,223,390 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

